WO2023045997A1 - Anticorps anti-claudine 18.2 et son utilisation - Google Patents
Anticorps anti-claudine 18.2 et son utilisation Download PDFInfo
- Publication number
- WO2023045997A1 WO2023045997A1 PCT/CN2022/120428 CN2022120428W WO2023045997A1 WO 2023045997 A1 WO2023045997 A1 WO 2023045997A1 CN 2022120428 W CN2022120428 W CN 2022120428W WO 2023045997 A1 WO2023045997 A1 WO 2023045997A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- amino acid
- antibody
- acid sequence
- variable region
- Prior art date
Links
- 230000027455 binding Effects 0.000 claims abstract description 69
- 239000000427 antigen Substances 0.000 claims abstract description 52
- 102000036639 antigens Human genes 0.000 claims abstract description 51
- 108091007433 antigens Proteins 0.000 claims abstract description 51
- 239000012634 fragment Substances 0.000 claims abstract description 29
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 17
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 12
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 12
- 201000011510 cancer Diseases 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 68
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 20
- -1 IL-11Rα Proteins 0.000 claims description 19
- 238000012217 deletion Methods 0.000 claims description 16
- 230000037430 deletion Effects 0.000 claims description 16
- 238000003780 insertion Methods 0.000 claims description 16
- 230000037431 insertion Effects 0.000 claims description 16
- 238000006467 substitution reaction Methods 0.000 claims description 16
- 230000035772 mutation Effects 0.000 claims description 14
- 241001529936 Murinae Species 0.000 claims description 11
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 102100030703 Interleukin-22 Human genes 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 4
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 108010002386 Interleukin-3 Proteins 0.000 claims description 3
- 108010002616 Interleukin-5 Proteins 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 108010002586 Interleukin-7 Proteins 0.000 claims description 3
- 108010002335 Interleukin-9 Proteins 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 108010074108 interleukin-21 Proteins 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 102100038078 CD276 antigen Human genes 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 2
- 101001044895 Homo sapiens Interleukin-20 receptor subunit beta Proteins 0.000 claims description 2
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 claims description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 2
- 101000795117 Homo sapiens Triggering receptor expressed on myeloid cells 2 Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims description 2
- 102000000589 Interleukin-1 Human genes 0.000 claims description 2
- 102100030236 Interleukin-10 receptor subunit alpha Human genes 0.000 claims description 2
- 101710146672 Interleukin-10 receptor subunit alpha Proteins 0.000 claims description 2
- 102100020788 Interleukin-10 receptor subunit beta Human genes 0.000 claims description 2
- 101710199214 Interleukin-10 receptor subunit beta Proteins 0.000 claims description 2
- 108090000177 Interleukin-11 Proteins 0.000 claims description 2
- 102000003815 Interleukin-11 Human genes 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 102100020790 Interleukin-12 receptor subunit beta-1 Human genes 0.000 claims description 2
- 101710103841 Interleukin-12 receptor subunit beta-1 Proteins 0.000 claims description 2
- 102100020792 Interleukin-12 receptor subunit beta-2 Human genes 0.000 claims description 2
- 101710103840 Interleukin-12 receptor subunit beta-2 Proteins 0.000 claims description 2
- 108090000176 Interleukin-13 Proteins 0.000 claims description 2
- 102000003816 Interleukin-13 Human genes 0.000 claims description 2
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims description 2
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 101800003050 Interleukin-16 Proteins 0.000 claims description 2
- 108050003558 Interleukin-17 Proteins 0.000 claims description 2
- 102000013691 Interleukin-17 Human genes 0.000 claims description 2
- 102100039879 Interleukin-19 Human genes 0.000 claims description 2
- 108050009288 Interleukin-19 Proteins 0.000 claims description 2
- 102100022706 Interleukin-20 receptor subunit alpha Human genes 0.000 claims description 2
- 101710174006 Interleukin-20 receptor subunit alpha Proteins 0.000 claims description 2
- 102100022705 Interleukin-20 receptor subunit beta Human genes 0.000 claims description 2
- 102000013264 Interleukin-23 Human genes 0.000 claims description 2
- 108010065637 Interleukin-23 Proteins 0.000 claims description 2
- 102100036672 Interleukin-23 receptor Human genes 0.000 claims description 2
- 102100040066 Interleukin-27 receptor subunit alpha Human genes 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 108090001007 Interleukin-8 Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 claims description 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 2
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 2
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 238000002659 cell therapy Methods 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 238000001415 gene therapy Methods 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 108090000681 interleukin 20 Proteins 0.000 claims description 2
- 102000004114 interleukin 20 Human genes 0.000 claims description 2
- 108010074109 interleukin-22 Proteins 0.000 claims description 2
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 claims description 2
- 108040010246 interleukin-27 receptor activity proteins Proteins 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 208000029824 high grade glioma Diseases 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 48
- 230000000694 effects Effects 0.000 description 27
- 239000002953 phosphate buffered saline Substances 0.000 description 22
- 229950007157 zolbetuximab Drugs 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 11
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 102000002029 Claudin Human genes 0.000 description 6
- 108050009302 Claudin Proteins 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 4
- 101150023212 fut8 gene Proteins 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 210000001578 tight junction Anatomy 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000000591 Tight Junction Proteins Human genes 0.000 description 3
- 108010002321 Tight Junction Proteins Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000003236 esophagogastric junction Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000002038 Claudin-18 Human genes 0.000 description 1
- 108050009324 Claudin-18 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000126130 Ganymedes Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000018553 digestive system adenoma Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000000882 gastrointestinal adenoma Diseases 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
Definitions
- the invention belongs to the field of biomedicine, and in particular relates to an anti-Claudin18.2 antibody and its application.
- Intercellular tight junction is a kind of transmembrane protein complex.
- the stability of tight junction needs the coordinated activities of several different proteins to maintain, and Claudin protein is the main protein that ensures the specificity of tight junction permeability. So far, 24 Claudin family members have been found in mammals, and each protein is specifically expressed in a certain tissue.
- the extracellular loop structure of the claudin protein connects to this structure of adjacent cells, bridging the cell layer and regulating the parallel traffic between the compartment and the basal layer.
- Claudin18 protein includes four transmembrane regions and two extracellular loops. Its N-terminal and C-terminal are in the cytoplasm. The molecular weight of the protein is about 26KD.
- the Claudin protein can be transformed into Claudin with different characteristics by selective cleavage. Isotypes: Claudin18.1 and Claudin18.2. Although there is only eight amino acid differences between the first extracellular domain of Claudin18.1 and Claudin18.2, the expression distribution is different.
- Claudin18.1 is selectively expressed in normal lung and gastric epithelium, while Claudin18.2 is only expressed in Expressed on transiently differentiated gastric epithelial cells, completely undetectable in any other normal human organ, but Claudin18.2 is significantly upregulated in a variety of malignant tumors, including 80% of gastrointestinal adenomas, 60% of pancreatic tumors , 30% esophageal cancer and 25% non-small cell lung cancer. In tumors, the tight junctions between cells are disrupted, and Claudin18.2 cannot perform its normal function. Therefore, Claudin18.2 is a suitable target for tumor therapy.
- IMAB362 also known as IMAB362
- IgG1 chimeric antibody against Claudin18.2 recognizes the first extracellular domain (ECD1) of Claudin18.2 with high affinity and specificity.
- ECD1 extracellular domain
- IMAB362 mediates cell killing via ADCC, CDC, induction of apoptosis via target cross-linking on the surface of tumor cells, and proliferation.
- ADCC extracellular domain
- CDC induction of apoptosis via target cross-linking on the surface of tumor cells
- IMAB362 efficiently lyses Claudin18.2-positive cells, including human gastric cancer cell lines in vitro and in vivo. Mice with Claudin18.2-positive cancer cell lines had a survival benefit, and when treated with IMAB362, up to 40% of mice showed regression of their tumors.
- Gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma is one of the most unmet medical needs of malignant tumors, and gastric cancer is also the third leading cause of cancer death worldwide. Therefore, the development of anti-Claudin18.2 antibodies and other drugs such as multifunctional and bifunctional antibodies has great significance for the treatment of some solid tumors, especially stomach-related tumors. However, there is currently no corresponding antibody developed and marketed.
- the inventors developed an anti-Claudin18.2 antibody with good performance, which does not bind to Claudin18.1, but can bind to Claudin18.2 with high affinity and specificity, and mediate Killing of Claudin 18.2 expressing target cells (eg tumor cells) by effector cells.
- target cells eg tumor cells
- the present invention provides an anti-Claudin18.2 antibody or an antigen-binding fragment thereof, which comprises a heavy chain variable region and a light chain variable region, and the heavy chain variable region comprises heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3,
- the light chain variable region comprises light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein,
- HCDR1 of the heavy chain variable region is selected from any amino acid sequence of SEQ ID NO: 1, 9, 15, 19, or has at least one amino acid sequence with any amino acid sequence of SEQ ID NO: 1, 9, 15, 19 A sequence that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical, or to SEQ ID NO: 1, Amino acid sequences with one or more (preferably 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to any amino acid sequence of 9, 15 and 19;
- HCDR2 of the heavy chain variable region selected from any amino acid sequence of SEQ ID NO: 2, 10, 16, 20, 21, 22, 23, 24, 25, or with SEQ ID NO: 2, 10, Any amino acid sequence of 16, 20, 21, 22, 23, 24, 25 has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, A sequence of 98%, 99% or more identity, or one or more (preferably 2 or 3) amino acid sequences of conservative amino acid mutations (preferably substitutions, insertions or deletions);
- HCDR3 of the heavy chain variable region selected from any amino acid sequence of SEQ ID NO: 3, 11, 17, 26, 27, 63, or with SEQ ID NO: 3, 11, 17, 26, 27, Any amino acid sequence of 63 is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical, Or an amino acid having one or more (preferably 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions) compared to any amino acid sequence of SEQ ID NO: 3, 11, 17, 26, 27, 63 sequence;
- LCDR1 of the light chain variable region is selected from any amino acid sequence of SEQ ID NO: 4, 28, or has at least 80%, 85%, 90% of any amino acid sequence of SEQ ID NO: 4, 28 , 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical sequences, or compared with any amino acid sequence of SEQ ID NO: 4, 28 Amino acid sequence with one or more (preferably 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions);
- LCDR2 of the light chain variable region is selected from any amino acid sequence of SEQ ID NO: 5, or has at least 80%, 85%, 90%, 91%, any amino acid sequence with any amino acid sequence of SEQ ID NO: 5 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical sequences, or have one or more ( Amino acid sequence of preferably 2 or 3) conservative amino acid mutations (preferably substitutions, insertions or deletions); and/or
- LCDR3 of the light chain variable region is selected from any amino acid sequence of SEQ ID NO: 6, 12, or has at least 80%, 85%, 90% of any amino acid sequence of SEQ ID NO: 6, 12 , 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical sequences, or compared with any amino acid sequence of SEQ ID NO: 6, 12
- An amino acid sequence with one or more (preferably 2 or 3) conservative amino acid mutations preferably substitutions, insertions or deletions).
- the HCDR1, HCDR2, and HCDR3 of the heavy chain variable region, and the LCDR1, LCDR2, and LCDR3 of the light chain variable region are selected from any amino acid sequence in the following (1)-(11):
- HCDR1 shown in SEQ ID NO: 1 HCDR2 shown in SEQ ID NO: 2
- HCDR3 shown in SEQ ID NO: 3 LCDR1 shown in SEQ ID NO: 4, shown in SEQ ID NO: 5
- LCDR2 shown in SEQ ID NO: 6 LCDR3 shown in SEQ ID NO: 6;
- HCDR1 shown in SEQ ID NO: 19 HCDR2 shown in SEQ ID NO: 20, HCDR3 shown in SEQ ID NO: 63, LCDR1 shown in SEQ ID NO: 28, shown in SEQ ID NO: 5 LCDR2, LCDR3 shown in SEQ ID NO: 6;
- HCDR1 shown in SEQ ID NO: 19 HCDR2 shown in SEQ ID NO: 21, HCDR3 shown in SEQ ID NO: 63, LCDR1 shown in SEQ ID NO: 28, shown in SEQ ID NO: 5 LCDR2, LCDR3 shown in SEQ ID NO: 6;
- HCDR1 shown in SEQ ID NO: 19 HCDR2 shown in SEQ ID NO: 22, HCDR3 shown in SEQ ID NO: 26, LCDR1 shown in SEQ ID NO: 28, shown in SEQ ID NO: 5 LCDR2, LCDR3 shown in SEQ ID NO: 6;
- HCDR1 shown in SEQ ID NO: 19 HCDR2 shown in SEQ ID NO: 23, HCDR3 shown in SEQ ID NO: 63, LCDR1 shown in SEQ ID NO: 28, shown in SEQ ID NO: 5 LCDR2, LCDR3 shown in SEQ ID NO: 6;
- HCDR1 shown in SEQ ID NO: 19 HCDR2 shown in SEQ ID NO: 24, HCDR3 shown in SEQ ID NO: 63, LCDR1 shown in SEQ ID NO: 28, shown in SEQ ID NO: 5 LCDR2, LCDR3 shown in SEQ ID NO: 6;
- HCDR1 shown in SEQ ID NO: 19 HCDR2 shown in SEQ ID NO: 25, HCDR3 shown in SEQ ID NO: 63, LCDR1 shown in SEQ ID NO: 28, shown in SEQ ID NO: 5 LCDR2, LCDR3 shown in SEQ ID NO: 6;
- HCDR1 shown in SEQ ID NO: 19 HCDR2 shown in SEQ ID NO: 23, HCDR3 shown in SEQ ID NO: 27, LCDR1 shown in SEQ ID NO: 28, shown in SEQ ID NO: 5 LCDR2, LCDR3 shown in SEQ ID NO: 6;
- HCDR1 shown in SEQ ID NO: 19 HCDR2 shown in SEQ ID NO: 24, HCDR3 shown in SEQ ID NO: 27, LCDR1 shown in SEQ ID NO: 28, shown in SEQ ID NO: 5 LCDR2, LCDR3 shown in SEQ ID NO:6.
- the present invention also provides an anti-Claudin18.2 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein:
- said heavy chain variable region has any amino acid sequence given by SEQ ID NO: 7, 13, 18, 29, 30, 31, 33, 34, 35, 36, 37,
- amino acid sequences of conservative amino acid mutations preferably substitutions, insertions or deletions
- said light chain variable region has any amino acid sequence given by SEQ ID NO: 8, 14, 32, 38;
- the heavy chain variable region and the light chain variable region are selected from any amino acid sequence in the following (1)-(11):
- the antibody is a murine antibody, a chimeric antibody, a humanized antibody, or a fully human antibody.
- the antibody is a monoclonal antibody.
- the anti-Claudin18.2 antibody or antigen-binding fragment thereof further comprises an Fc region selected from mouse IgG1, IgG2a, IgG2b and/or IgG3, or selected from rat IgG1, IgG2a , IgG2b and/or IgG2c.
- the anti-Claudin18.2 antibody or antigen-binding fragment thereof further comprises an Fc region selected from human IgG1, IgG2, IgG3 and/or IgG4.
- the present invention also provides a nucleic acid molecule encoding the anti-Claudin18.2 antibody or antigen-binding fragment thereof described in any one of the above.
- the present invention also provides a multifunctional fusion protein comprising the anti-Claudin18.2 antibody or antigen-binding fragment thereof described in any one of the above.
- the anti-Claudin18.2 antibody or antigen-binding fragment thereof further comprises one or more second antibodies or antigen-binding portions thereof that specifically bind to other antigens.
- the antigen that binds the second antibody or antigen-binding portion thereof is selected from tumor-associated antigens (TAAs) or immune checkpoints.
- TAAs tumor-associated antigens
- immune checkpoints immune checkpoints
- the immune checkpoint is PD-L1, CTLA4, PD-L2, PD-1, 4-1BB, CD47, TIGIT, GITR, TIM3, ILT4, TNFR2, TREM2, LAG3, CD27, B7H3, or B7H4.
- cytokines are also included.
- the cytokine is selected from IL-1, IL-2, IL-2R ⁇ , IL-2R ⁇ , IL-3, IL-3R ⁇ , IL-4, IL-4R ⁇ , IL-5, IL- 5R ⁇ , IL-6, IL-6R ⁇ , IL-7, IL-7R ⁇ , IL-8, IL-9, IL-9R ⁇ , IL-10, IL-10R1, IL-10R2, IL-11, IL-11R ⁇ , IL-12, IL-12R ⁇ , IL-12R ⁇ 2, IL-12R ⁇ 1, IL-13, IL-13R ⁇ , IL-13R ⁇ 2, IL-14, IL-15, IL-15R ⁇ sushi, IL-16, IL-17, IL- 18.
- IL-19 IL-20, IL-20R1, IL-20R2, IL-21, IL-21R ⁇ , IL-22, IL-23, IL-23R, IL-27R, IL-31R, TGF, VEGF, IFN ⁇ , IFN ⁇ or GM-CSF.
- the present invention also provides the use of any one of the anti-Claudin18.2 antibodies or antigen-binding fragments thereof or any one of the multifunctional fusion proteins described above in the preparation of drugs for treating cancer.
- the cancer is lung cancer, liver cancer, melanoma, glioblastoma, head and neck cancer, esophageal cancer, gastric cancer, prostate cancer, ovarian cancer, bladder cancer, pancreatic cancer, gastric cancer, colon cancer, cervical cancer, or associated tumors.
- the use is achieved by one or more of tumor immunotherapy, cell therapy, and gene therapy.
- the present invention also provides a pharmaceutical composition, which comprises the anti-Claudin18.2 antibody or antigen-binding fragment thereof described in any one of the above and a pharmaceutically acceptable carrier, diluent or excipient.
- the present invention also provides a pharmaceutical composition, which comprises any one of the above-mentioned multifunctional fusion proteins and a pharmaceutically acceptable carrier, diluent or excipient.
- mAb monoclonal antibody
- VH Antibody heavy chain variable region
- VL antibody light chain variable region
- FR Antibody framework region, that is, the amino acid residues in the antibody variable region except CDR residues
- IgG Immunoglobulin G
- antibody refers to natural immunoglobulins or immunoglobulins prepared by partial or complete synthesis. Antibodies can be reconstituted and isolated from natural resources such as plasma or serum where the antibodies naturally exist, or culture supernatants of hybridoma cells producing antibodies, animal immune serum, or phage library screening. Alternatively, it can be partially or completely synthesized by using a technique of gene recombination or the like. Preferred antibodies include, for example, antibodies to immunoglobulin isotypes or subclasses of these isotypes. Known human immunoglobulins include nine classes (isotypes) of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, and IgM. Among these isotypes, antibodies of the invention may comprise IgG1, IgG2, IgG3 and/or IgG4.
- the term “monoclonal antibody” refers to a homogeneous antibody directed only against a specific antigenic epitope. In contrast to common polyclonal antibody preparations, which typically include different antibodies directed against different antigenic determinants (epitopes), each monoclonal antibody is directed against a single antigenic determinant on the antigen.
- the modifier "monoclonal” indicates the homogeneous character of the antibody and is not to be construed as requiring that the antibody be produced by any particular method.
- the monoclonal antibodies of the invention are preferably produced by recombinant DNA methods, or obtained by screening methods as described elsewhere herein.
- murine antibody in the present invention refers to a monoclonal antibody prepared according to the knowledge and skills in the art. In preparation, test subjects are injected with the antigen, and hybridomas expressing antibodies having the desired sequence or functional properties are isolated.
- chimeric antibody is an antibody that fuses the variable region of a murine antibody with the constant region of a human antibody, which can reduce the immune response induced by the murine antibody.
- To establish a chimeric antibody it is necessary to first establish a hybridoma that secretes a mouse-derived specific monoclonal antibody, then clone the variable region gene from the mouse hybridoma cell, and then clone the constant region gene of the human antibody as required, and then clone the variable region gene of the mouse
- the gene is connected with the human constant region gene to form a chimeric gene and then inserted into a human vector, and finally the chimeric antibody molecule is expressed in a eukaryotic industrial system or a prokaryotic industrial system.
- humanized antibody also known as CDR-grafted antibody, refers to an antibody produced by grafting mouse CDR sequences into human antibody variable region frameworks, that is, different types of human germline antibody framework sequences. It can overcome the strong heterologous reaction induced by chimeric antibodies due to carrying a large number of mouse protein components.
- Partial antibodies as used herein are immunoglobulin molecules composed of two pairs of polypeptide chains, each pair having one light chain (LC) and one heavy chain (HC).
- Each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region (CH).
- the heavy chain constant region consists of 3 domains (CH1, CH2 and CH3).
- Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL), or only a light chain constant region (CL).
- the light chain constant region consists of one domain, CL.
- the constant domains are not directly involved in antibody-antigen binding, but exhibit various effector functions, such as mediating immunoglobulin interactions with host tissues or factors, including various cells of the immune system (e.g., effector cells) and classical complement Binding of the first component (C1q) of the system.
- the VH and VL regions can also be subdivided into regions of high variability called complementarity determining regions (CDRs) interspersed with more conserved regions called framework regions (FRs).
- CDRs complementarity determining regions
- FRs framework regions
- Each VH and VL is composed of 3 CDRs and 4 FRs arranged in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 from the amino terminus to the carboxy terminus.
- the variable regions (VH and VL) of each heavy chain/light chain pair form the antigen binding site, respectively.
- antigen-binding fragment of an antibody refers to a polypeptide fragment of an antibody, such as a polypeptide fragment of a full-length antibody, that retains the ability to specifically bind to the same antigen to which the full-length antibody binds, and/or competes with the full-length antibody for binding of the antigen. specifically binds, which is also referred to as an "antigen-binding moiety".
- Antigen-binding fragments of antibodies can be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies.
- Non-limiting examples of antigen-binding fragments include Fab, Fab', F(ab')2, Fd, Fv, dAb and complementarity determining region (CDR) fragments, single chain antibodies (e.g., scFv), chimeric antibodies, diabodies (diabody), linear antibody (linear antibody), nanobody (such as technology from Ablynx), domain antibody (such as technology from Domantis), and such polypeptides, which comprise at least a portion of an antibody sufficient to confer polypeptide-specific antigen-binding capacity .
- CDR complementarity determining region
- polypeptide refers to a chain of amino acids of any length, regardless of modifications such as phosphorylation or glycosylation.
- polypeptide includes proteins and fragments thereof.
- Polypeptides may be "exogenous” in the sense that they are “heterologous”, ie, foreign to the host cell utilized, eg, human polypeptides produced by bacterial cells.
- a polypeptide is disclosed herein as a sequence of amino acid residues. Those sequences are written left to right in amino-terminal to carboxy-terminal orientation.
- amino acid residue sequences are designated by three-letter or one-letter codes, as follows: alanine (Ala, A), arginine (Arg, R), asparagine (Asn, N), asparagine Aspartic acid (Asp, D), cysteine (Cys, C), glutamine (Gln, Q), glutamic acid (Glu, E), glycine (Gly, G), histidine (His, H), Isoleucine (Ile, I), Leucine (Leu, L), Lysine (Lys, K), Methionine (Met, M), Phenylalanine (Phe, F) , proline (Pro, P), serine (Ser, S), threonine (Thr, T), tryptophan (Trp, W), tyrosine (Tyr, Y) and valine (Val, V).
- host cell refers to a cell that has been or can be transformed with a nucleic acid sequence and thereby express a selected gene of interest.
- the term includes progeny of a parental cell, whether or not the progeny is morphologically or genetically identical to the original parental cell, as long as the progeny has the selected gene of interest.
- Commonly used host cells include bacteria, yeast, mammalian cells, and the like.
- vector refers to a nucleic acid molecule capable of multiplying another nucleic acid to which it has been linked.
- the term includes vectors that are self-replicating nucleic acid structures as well as vectors that are incorporated into the genome of a host cell into which they are introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operably linked, and are referred to herein as "expression vectors.”
- pharmaceutically acceptable carrier includes any standard pharmaceutical carrier, such as phosphate buffered saline, water, and emulsions, as well as various types of wetting agents.
- percent (%) amino acid sequence identity is defined as the percentage of amino acid residues in a candidate sequence that are identical to those in a reference polypeptide sequence after aligning the sequences and introducing gaps, if necessary, to obtain the maximum percent sequence identity . Alignment for purposes of determining percent amino acid sequence identity can be performed in various ways that are within the skill in the art, for example, using publicly available computer software such as the BLAST software or the FASTA program package.
- the CDR of the anti-Claudin18.2 antibody of the present invention refers to the hypervariable region of the heavy chain and light chain of the immunoglobulin, wherein, SEQ ID NO: 1, 2, 3, 4, 5, 6, 9, 10, 11, 12
- SEQ ID NO: 1, 2, 3, 4, 5, 6, 9, 10, 11, 12 The CDR amino acid positions of , 15, 16, and 17 are defined according to Kabat, and the CDR amino acid positions of SEQ ID NO: 19, 20, 21, 22, 23, 24, 25, 26, 27, and 63 are defined according to AbM.
- the term "specific" means that one of the molecules involved in specific binding does not show any significant binding to a molecule or molecules other than the binding partner molecules.
- the term is used when a domain comprising an antibody variable region is specific for a particular epitope among epitopes in an antigen.
- an antigen-binding molecule comprising an antibody variable region-containing domain can bind various antigens having the epitope.
- epitope refers to an antigenic determinant in an antigen, and refers to an antigenic site to which a domain of an antigen-binding molecule comprising an antibody variable region disclosed in this specification binds. Therefore, an epitope can be defined according to its structure. In addition, the epitope can also be defined based on the antigen-binding activity of the antigen-binding molecule that recognizes the epitope. When the antigen is a peptide or polypeptide, the epitope can be specified by the amino acid residues forming the epitope; when the epitope is a sugar chain, the epitope can be determined by its specific sugar chain structure.
- positive control antibody refers to natural or engineered cells capable of binding to or expressing a target protein.
- isotype control refers to the use of the same species source, the same subtype, the same dose, the same immunoglobulin and subtype of immunoglobulin, the same marker, etc. as the experimental sample in the same experiment, used in the elimination experiment.
- the effect of the experimental background of the non-specific binding sample on the experimental value is used as a negative control to illustrate the experimental effect.
- the murine, chimeric or humanized monoclonal antibody combined with Claudin18.2 provided by the present invention has higher Claudin18.2 binding activity, ADCC activity and CDC activity than the prior art antibody.
- the anti-Claudin18.2 antibody of the present invention is humanized, and the modified antibody has Claudin18.2 binding activity equivalent to that of the original antibody, and its affinity is relatively stable, which can ensure the specificity of the antibody. Its CDC activity is comparable to that of the original antibody. Also basically the same.
- Figure 1 shows the binding activity of murine antibodies 1, 2, and 3 to human Claudin18.2-PANC1.
- Figure 2 shows the binding activity of chimeric antibodies 4 and 5 to human Claudin18.2-CHOK1.
- Figure 3 shows the binding activity of chimeric antibody 6 to human Claudin18.2-CHOK1.
- Figure 4 shows the binding activity of chimeric antibodies 4 and 5 to human Claudin18.2-PANC1.
- Figure 5 shows the binding activity of humanized antibodies 7, 8, and 9 to human Claudin18.2-CHOK1.
- Fig. 6 shows the binding activity of humanized antibody 10 to human Claudin18.2-CHOK1.
- Fig. 7 shows the binding activity of humanized antibodies 11 and 12 to human Claudin18.2-CHOK1.
- Figure 8 shows the CDC activity of murine antibodies 1, 2, and 3 against human Claudin18.2-CHOK1.
- Figure 9 shows the CDC activity of chimeric antibodies 4 and 5 against human Claudin18.2-CHOK1.
- Figure 10 shows the CDC activity of chimeric antibody 6 against human Claudin18.2-CHOK1.
- Figure 11 shows the CDC activity of humanized antibody 10 against human Claudin18.2-CHOK1.
- Figure 12 shows the CDC activity of humanized antibodies 11 and 12 against human Claudin18.2-CHOK1.
- Figure 13 shows the ADCC activity of chimeric antibodies 4 and 5 against human Claudin18.2-PANC-1.
- Figure 14 shows the ADCC activity of chimeric antibody 6 against human Claudin18.2-PANC-1.
- Figure 15 shows the binding activity of chimeric antibodies A, B, C, D, E, F, G to human Claudin18.2-CHOK1.
- Figure 16 shows the binding activity of humanized antibodies H, I, J, K, L, M, N, O, P, Q, R to human Claudin18.2-CHOK1, with Z1 as the control antibody.
- Figure 17 shows the binding activity of humanized antibodies H, I, J, K, L, M, N, O, P, Q, R to human Claudin18.2-CHOK1, using IMAB362 as a control antibody.
- Figure 18 is the CDC activity of humanized antibodies H, J, L on human Claudin18.2-CHOK1.
- 293 cells overexpressing human Claudin18.2 were used as an immunogen to immunize Balb/c mice for 3-4 times, one week after each immunization with CHOK1 and cells coated with CHOK1 overexpressing human Claudin18.2 -ELISA to detect serum titer. After the titer reached the requirement for fusion, the cells were used for booster immunization 2 weeks after the last immunization.
- Antibody 12 SEQ ID NO: 50 SEQ ID NO: 49
- the control antibody of antibody 1-6 is the FUT8 gene silenced IMAB362 obtained by the sugar-knocking process described in patent application 202110752316.6, and the control antibody of humanized antibody 7-12 is IMAB362
- the isotype control antibody start at 10ug/ml, dilute 3 times, perform 7 serial dilutions, set 2 parallel wells, 50ul/well.
- NK cell count of the target cells Take out the NK cell count of the target cells, and set the number of cells to 5 ⁇ 10 4 /50ul/well. Centrifuge at 1000rpm for 4min. Incubate at 37°C for 3.25h. Set ST well (only target cells), SE well (only effector cells), BV well (200ul dilution), BM well (200ul dilution) and M well (50ul effector cells + 150ul dilution). Add 20ul of lysate to the BM and BV wells, and incubate at 37°C for 45min.
- the results of ADCC activity showed that chimeric antibodies 4, 5, and 6 had similar inhibitory effects on ADCC activity in vitro as the control antibody.
- the control antibody is FUT8 gene-silenced IMAB362 obtained according to the sugar knockout process described in patent application 202110752316.6. Compared with IMAB362 without FUT8 gene knockout, the ADCC effect of FUT8 gene-silenced IMAB362 is increased by 5 times.
- the in vitro ADCC activity inhibitory effects of chimeric antibodies 4, 5, and 6 are equivalent to those of the control antibody. It can be seen that the in vitro ADCC activity inhibitory effects of chimeric antibodies 4, 5, and 6 significantly.
- the binding activity of chimeric antibodies A, B, C, D, E to human Claudin18.2-CHOK1 was basically the same as that of the control antibody to human Claudin18.2-CHOK1, and the binding activity of chimeric antibody F and chimeric antibody G to human The binding activity of Claudin18.2-CHOK1 was lower than that of the control antibody to human Claudin18.2-CHOK1.
- the binding activity of humanized anti-H, I, J, K, L, M, N, O, P, Q, R to human Claudin18.2-CHOK1 and the binding activity of control antibody Z1 to human Claudin18.2-CHOK1 Basically the same;
- the binding activity of humanized antibodies H, I, J, K, L, M, N, O, P, Q, R to human Claudin18.2-CHOK1 is the same as that of the control antibody IMAB362 to human Claudin18.2-CHOK1
- the combined activity effect is basically the same.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne un anticorps anti-claudine 18.2 ou un fragment de liaison à l'antigène de celui-ci et son utilisation. La présente invention concerne également un anticorps bispécifique, un anticorps multispécifique, une protéine de fusion multifonctionnelle et une composition associée contenant l'anticorps, ainsi qu'une utilisation dans la préparation d'un médicament pour le traitement du cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280052157.1A CN117897403A (zh) | 2021-09-24 | 2022-09-22 | 一种抗Claudin18.2抗体及其应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021120034 | 2021-09-24 | ||
CNPCT/CN2021/120034 | 2021-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023045997A1 true WO2023045997A1 (fr) | 2023-03-30 |
Family
ID=85720078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/120428 WO2023045997A1 (fr) | 2021-09-24 | 2022-09-22 | Anticorps anti-claudine 18.2 et son utilisation |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117897403A (fr) |
WO (1) | WO2023045997A1 (fr) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104321345A (zh) * | 2012-05-09 | 2015-01-28 | 加尼梅德药物公司 | 用于癌症诊断的针对密蛋白18.2的抗体 |
CN109762067A (zh) * | 2019-01-17 | 2019-05-17 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
CN110857322A (zh) * | 2018-08-22 | 2020-03-03 | 瑞阳(苏州)生物科技有限公司 | 抗人claudin 18.2单克隆抗体及其应用 |
CN112574307A (zh) * | 2019-09-29 | 2021-03-30 | 迈威(上海)生物科技股份有限公司 | 抗人Claudin18.2抗体及其应用 |
WO2021130291A1 (fr) * | 2019-12-23 | 2021-07-01 | SOTIO a.s. | Anticorps anti-claudin 18.2 spécifiques d'une tumeur |
WO2021160155A1 (fr) * | 2020-02-10 | 2021-08-19 | 上海诗健生物科技有限公司 | Anticorps anti-claudine 18.2 et utilisation associée |
EP3872093A1 (fr) * | 2018-10-22 | 2021-09-01 | Shanghai Genbase Biotechnology Co., Ltd. | Anticorps anti-cldn28.2 et ses applications |
-
2022
- 2022-09-22 CN CN202280052157.1A patent/CN117897403A/zh active Pending
- 2022-09-22 WO PCT/CN2022/120428 patent/WO2023045997A1/fr active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104321345A (zh) * | 2012-05-09 | 2015-01-28 | 加尼梅德药物公司 | 用于癌症诊断的针对密蛋白18.2的抗体 |
CN110857322A (zh) * | 2018-08-22 | 2020-03-03 | 瑞阳(苏州)生物科技有限公司 | 抗人claudin 18.2单克隆抗体及其应用 |
EP3872093A1 (fr) * | 2018-10-22 | 2021-09-01 | Shanghai Genbase Biotechnology Co., Ltd. | Anticorps anti-cldn28.2 et ses applications |
CN109762067A (zh) * | 2019-01-17 | 2019-05-17 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
CN112574307A (zh) * | 2019-09-29 | 2021-03-30 | 迈威(上海)生物科技股份有限公司 | 抗人Claudin18.2抗体及其应用 |
WO2021130291A1 (fr) * | 2019-12-23 | 2021-07-01 | SOTIO a.s. | Anticorps anti-claudin 18.2 spécifiques d'une tumeur |
WO2021160155A1 (fr) * | 2020-02-10 | 2021-08-19 | 上海诗健生物科技有限公司 | Anticorps anti-claudine 18.2 et utilisation associée |
Also Published As
Publication number | Publication date |
---|---|
CN117897403A (zh) | 2024-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11161904B2 (en) | Anti-PD-1 antibody and use thereof | |
CN110305210B (zh) | 新型抗体分子、其制备方法及其用途 | |
US11365260B2 (en) | Agonistic 4-1BB monoclonal antibody | |
IL264964B2 (en) | Anti-CTLA4 and anti-PD1 bifunctional antibody, pharmaceutical preparation thereof and use thereof | |
JP2019519492A5 (fr) | ||
WO2017059387A1 (fr) | Molécules de liaison à chaîne j modifiée | |
US11525005B2 (en) | Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof | |
WO2021218684A1 (fr) | Anticorps bispécifique tétravalent, son procédé de préparation et son utilisation | |
WO2021013065A1 (fr) | Fragment d'anticorps fab anti-vegf humanisé et son utilisation | |
CN116940598A (zh) | 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体 | |
WO2021143914A1 (fr) | Anticorps anti-ox40, son procédé de production et son application | |
WO2021088904A1 (fr) | Anticorps dirigé contre le ligand 1 de la mort cellulaire programmée humain (pd-l1) et son utilisation | |
JP2020525432A (ja) | 非対称ヘテロ二量体FC−SCFV融合抗GLOBO Hおよび抗CD3二重特異的抗体およびがん療法(caner therapy)におけるその使用 | |
WO2022267936A1 (fr) | Anticorps spécifiquement lié à ceacam5 glycosylé | |
WO2023045997A1 (fr) | Anticorps anti-claudine 18.2 et son utilisation | |
CA3231761A1 (fr) | Anticorps anti-cd3 humain et son utilisation | |
KR20200063147A (ko) | Pdl1 표적화 항체 및 이의 사용 방법 | |
WO2023198019A1 (fr) | Anticorps dirigé contre ceacam5 et ceacam6 et son utilisation | |
WO2023193732A1 (fr) | Anticorps anti-ccr8 ou fragment de liaison à l'antigène de celui-ci | |
CN112521499B (zh) | 抗cxcl13抗体及其用途 | |
CN115124620B (zh) | 一种能够激活nk细胞的抗体及其应用 | |
WO2023280042A1 (fr) | Anticorps anti-cd24 et son utilisation | |
JP7392200B2 (ja) | グリコシル化ceacam5に特異的に結合した抗体 | |
WO2023134716A1 (fr) | Anticorps bispécifique se liant à b7h3 et nkp30 et son utilisation | |
WO2024037627A1 (fr) | Anticorps bispécifique et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22872042 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280052157.1 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |